Glauconix Biosciences Inc, a specialty pharmaceutical company, announced yesterday that it has named Kimberly Southern as its new chief operating officer.
Southern has more than 20 years of experience in building and leading companies in various industries, most recently as COO at New England Peptide in Gardner, Massachusetts.
In her new role, she will steer the company's business strategies, drive operational execution, and further develop the company's R&D initiatives and intellectual property portfolio.
Glauconix is located on the SUNY Polytechnic Institute Campus in Albany, which is affiliated with the Center for Advanced Technology in Nanomaterials and Nanoelectronics (CATN2).
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits
Frost & Sullivan names Abzena a market-leading ADC CDMO
Vulcan Two signs five-year ERP licence agreement to support ePharmacy expansion
SportsMed Physical Therapy named Physical Therapy Company of the Year